Filing Details
- Accession Number:
- 0001140361-11-027143
- Form Type:
- 4/A
- Zero Holdings:
- No
- Publication Time:
- 2011-05-13 07:52:02
- Reporting Period:
- 2011-05-10
- Filing Date:
- 2011-05-13
- Accepted Time:
- 2011-05-13 07:52:02
- Original Submission Date:
- 2011-05-12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1124105 | Targacept Inc | TRGT | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1198177 | Steven Burrill | C/O Targacept, Inc. 200 East First Street, Suite 300 Winston-Salem NC 27101 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2011-05-10 | 16,948 | $9.37 | 16,948 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-05-10 | 16,948 | $24.04 | 0 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2011-05-10 | 2,000 | $24.13 | 0 | No | 4 | S | Indirect | By Burrill & Company LLC |
| Common Stock | Acquisiton | 2011-05-12 | 10,552 | $9.37 | 10,552 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2011-05-12 | 7,500 | $9.27 | 18,052 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2011-05-12 | 7,500 | $7.10 | 25,552 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2011-05-12 | 7,500 | $2.71 | 33,052 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2011-05-12 | 33,052 | $23.88 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Indirect | By Burrill & Company LLC |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-05-10 | 16,948 | $0.00 | 16,948 | $9.37 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-05-12 | 3,052 | $0.00 | 3,052 | $9.37 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-05-12 | 7,500 | $0.00 | 7,500 | $9.37 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-05-12 | 7,500 | $0.00 | 7,500 | $9.27 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-05-12 | 7,500 | $0.00 | 7,500 | $7.10 |
| Common Stock | Stock Option (Right to Buy) | Disposition | 2011-05-12 | 7,500 | $0.00 | 7,500 | $2.71 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 3,052 | 2007-05-14 | 2017-05-13 | No | 4 | M | Direct |
| 0 | 2007-05-14 | 2017-05-13 | No | 4 | M | Direct |
| 0 | 2007-06-12 | 2017-05-13 | No | 4 | M | Direct |
| 0 | 2008-06-20 | 2017-06-19 | No | 4 | M | Direct |
| 0 | 2009-06-09 | 2018-07-01 | No | 4 | M | Direct |
| 0 | 2010-06-09 | 2019-06-16 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 0 | Indirect | By Burrill Biotechnology Capital Fund L.P. |
Footnotes
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.00 to $24.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.99 to $24.23, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The reporting person is the chief executive officer of Burrill & Company LLC. The reporting person disclaims beneficial ownership of securities owned by Burrill & Company LLC except to the extent of his pecuniary interest therein.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 to $24.04, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Reflects a prior pro rata distribution by Burrill Biotechnology Capital Fund L.P. of all shares of the issuer previously reported as indirectly held by the reporting person as the managing member of Burrill & Company (Biotechnology GP), LLC, the general partner of Burrill Biotechnology Capital Fund L.P. The reporting person disclaims beneficial ownership of securities owned by Burrill Biotechnology Capital Fund L.P. except to the extent of his pecuniary interest therein.
Billionaire Hedge Funds
